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surgery: a meta-analysis of four randomized
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Guixiang Liao1, Zhihong Zhao2, Shuhui Lin1, Rong Li1, Yawei Yuan1*, Shasha Du1, Jiarong Chen1 and Haijun Deng3Abstract
Background: Robotic-assisted laparoscopy is popularly performed for colorectal disease. The objective of this
meta-analysis was to compare the safety and efficacy of robotic-assisted colorectal surgery (RCS) and
laparoscopic colorectal surgery (LCS) for colorectal disease based on randomized controlled trial studies.
Methods: Literature searches of electronic databases (Pubmed, Web of Science, and Cochrane Library) were
performed to identify randomized controlled trial studies that compared the clinical or oncologic outcomes of
RCS and LCS. This meta-analysis was performed using the Review Manager (RevMan) software (version 5.2) that
is provided by the Cochrane Collaboration. The data used were mean differences and odds ratios for continuous
and dichotomous variables, respectively. Fixed-effects or random-effects models were adopted according to
heterogeneity.
Results: Four randomized controlled trial studies were identified for this meta-analysis. In total, 110 patients
underwent RCS, and 116 patients underwent LCS. The results revealed that estimated blood losses (EBLs),
conversion rates and times to the recovery of bowel function were significantly reduced following RCS
compared with LCS. There were no significant differences in complication rates, lengths of hospital stays,
proximal margins, distal margins or harvested lymph nodes between the two techniques.
Conclusions: RCS is a promising technique and is a safe and effective alternative to LCS for colorectal surgery.
The advantages of RCS include reduced EBLs, lower conversion rates and shorter times to the recovery of bowel
function. Further studies are required to define the financial effects of RCS and the effects of RCS on long-term
oncologic outcomes.
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Minimally invasive surgery for colorectal disease was
introduced in 1991 [1]. Such surgery has been widely
used worldwide and has become increasingly popular.
However, technical barriers, including unstable video
camera imaging, loss of dexterity and a steep learning
curve, preclude the widespread adoption of minimally
invasive surgery techniques for colorectal disease. To
overcome these technical drawbacks, robotic surgical
systems were introduced. Robotic laparoscopic colorectal* Correspondence: yuanyw12@163.com
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unless otherwise stated.surgery (RCS) was first reported in 2002 [2]. Since
then, many studies of RCS have been widely reported
[3-5]. RCS has some advantages over conventional
laparoscopic surgery (LCS). These advantages include
a three-dimensional image, convenient movements of
the robotic arm, no tremor, motion scaling, a short
learning curve, dexterity and ambidextrous capability
[4,6,7]. Some studies have already proven that robotic
laparoscopic colorectal surgery is associated with cer-
tain benefits compared to conventional laparoscopic
colorectal surgery [8-10]. Additionally, the learning
curve for robotic surgery is short [11]. However, the
relative merits of RCS versus LCS are controversial.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flow chart of the literature search.
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http://www.wjso.com/content/12/1/122The aim of this study was to compare the efficacy and
safety of RCS and LCS via a meta-analysis of the available
randomized controlled trials (RCTs).Methods
Research method
Two authors (XGL, HZZ) participated in this search to
independently identify all published RCT studies com-
paring RCS and LCS. The Pubmed, Web of Science
and Cochrane Library databases were searched. The
following medical subject heading terms and key wordsTable 1 General characteristics of the studies and participant
Author Year Country Group N Sex BMI ASA grade
M/F I/II/III/IV
Baik SH 2008 Korea RCS 18 14/4 22.8 (1.8) 12/6/0/0
LCS 18 14/4 24.0 (2.5) 9/6/1/1
Jimenez RR 2011 Spain RCS 28 12/16 28.59 (2.5) 14/14a
LC S 28 17/11 26.75 (5.6) 20/8a
Park JS 2012 Korea RCS 35 14/21 24.4 (2.5) 15/16/4/0
LCS 35 16/19 23.8 (2.7) 21/12/2/0
Patriti A 2009 Italy RCS 29 11/18 24 (6.2) 2/13/14/0
LCS 37 12/25 25.4 (6.44) 2/14/21/0
Values are expressed as mean (SD) or number. BMI, body mass index; ASA, America
laparoscopic colorectal surgery; M/F, male/female. a(I + II)/ III; b(T1 + T2)/T3.were used: robotic; telerobotic; colorectal; colon; rectal;
random. None of the searches had any language
limitations, and the most recent search time was 1
March 2013.
Inclusion criteria
For inclusion in this meta-analysis, the studies were
required to meet the following criteria: (1) RCTs; (2)
studies comparing the efficacy and safety of RCS and
LCS for the treatment of colorectal disease; (3) studies
that effectively reported both primary results and data
adequate for meta-analysis.
Data extraction
The effective data from all eligible RCTs were extracted
by two reviewers (XGL, HZZ). The extracted data
included the following: first author; year and country of
publication; surgical technique; operation type; basic
patient characteristics, including age, body mass index
(BMI), number of patients, diagnosis, tumor stage, in-
traoperative data, postoperative data; and pathological
details including operation time, estimated blood loss,
open conversion rate, time to recovery of bowel func-
tion, length of hospital stay, complication rate, proximal
margin, distal margin, harvested lymph nodes and cost.
All available data were extracted from the relevant texts,
tables and figures. In cases of disagreement about whether
a study was suitable for inclusion in the meta-analysis, an
additional reviewer (WYY) assessed the article and made
the final decision.
Risk of bias
Two reviewers (XGL, HZZ) independently evaluated the
bias of each study using the Cochrane tools [12]. The as-
sessment item included sequence generation, allocation
of sequence concealment, blinding of participants and
personnel, blinding of outcomes and assessments, in-
complete outcome data, selective outcome reporting ands
Age, years Disease Tumor stage Operation type
I/ II/III/IV
57.3 (6.3) Rectal cancer 5/4/9/0 Tumor-specific
mesorectal excision
62.0 (9.0) 5/4/9/0
68.0 (9.1) Sigmoid colon cancer
and rectal cancer
15/13b Total or subtotal
mesorectal excision
61.5 (15.0) 21/7b




68 (10) Rectal cancer 11/9/7/2 Total mesorectal
excision
69 (10) 17/8/10/2
n Society of Anesthesiologists; RCS, robotic-assisted colorectal surgery; LCS,
Table 2 Data extracted from the included studies
Study Group N Operation time,
minutes
EBL, ml Open conversion
events, n










Baik SH RCS 18 217.1 (51.6) N/A 0 1.8 (0.4) 4 6.9 (1.3) 10.9 (1.7) 4 (1.1) 20.1 (9.1) N/A
LCS 18 204.3 (56.9) 2 2.4 (1.3) 1 8.7 (1.7) 10.3 (3.6) 3.7 (1.1) 17.4 (10.6)
Jimenez RR RCS 28 159.4 (43.5) N/A 2 N/A 4 N/A N/A 4.8 (1.6) 17.6 (9.2) N/A
LCS 28 135.1 (29.2) 2 4 3.8 (0.7) 14.9 (8.7)
Park JS RCS 35 195 (41) 35.8 (26.3) 0 2.6 (1.4) 6 7.9 (4.1) 18.6 (7.3) 18 (9) 29.9 (14.7) 12,235 (1,907.9)
LCS 35 130 (43) 56.8 (31.3) 0 2.9 (2.2) 7 8.3 (4.2) 18.3 (9.9) 14.5 (8) 30.8 (13.3) 10,320.7 (1,607.7)
Patriti A RCS 29 202 (12) 137.4 (156) 0 N/A 9 11.9 (7. 5) N/A 2.1 (0.9) 10.3 (4) N/A
LCS 37 208 (7) 127 (169) 7 7 9.6 (6.9) 4.5 (7.2) 11.2 (5)



















Figure 2 Risk of bias graph. (+), low risk of bias; (−), high risk of
bias; (?), unclear risk of bias.
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reviewer (WYY) discussed the issues with the group
and made a final conclusion.
Statistical analyses
This meta-analysis was performed using the Review
Manager (RevMan) software, version 5.2, provided byFigure 3 Risk of bias summary.the Cochrane Collaboration. Dichotomous variables
were analyzed using estimations of the odds ratio (OR)
and 95% CI, and continuous variables were analyzed
using weighted mean difference (WMD) and 95% CI.
Fixed-effects models or random-effects models were
applied. Heterogeneity was evaluated using χ2 and I2
tests. We considered heterogeneity to be present when
the I2 statistic was >50%, and random-effects models
were adopted in these cases. However, when the I2 statistic




A total of 71 potentially relevant articles were identified,
and the selection process is illustrated in Figure 1. After
examination of the titles, abstracts and full texts, four
published RCT studies [13-16] were found to meet all of
the inclusion criteria and were entered into this meta-
analysis. In total, 110 patients underwent RCS, and 116
patients underwent LCS. One study of right-sided
colonic carcinoma [13], two studies of rectal cancer
[14,15], and another study that included sigmoid colon
cancer and rectal cancer [16] were reported. Information
about the general characteristics of the studies and the
participants is listed in Table 1, and the extracted data are
shown in Table 2.
Risk of bias assessment
All of the studies were RCTs, but none were double- or
even single-blinded. Assessments of the risk of bias are
illustrated in Figure 2 and Figure 3.
Meta-analysis
Operation times
All four of the studies reported operation times. Two
of the four studies indicated a tendency toward longer
operation times for the RCS groups than for the LCS
Figure 4 Meta-analysis of the operation times shown as a forest plot between robotic-assisted colorectal surgery (RCS) and laparoscopic
colorectal surgery (LCS). The mean differences with 95% CIs are shown.
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tween the two groups were reported in the other two
studies [14,15]. The pooled data revealed that the opera-
tive times were not significantly different between the two
techniques (WMD 23.89, 95% CI 12.09 to 59.87; P = 0.19),
but the heterogeneity was high (P <0.001, I2 = 94%)
(Figure 4).
Estimated blood losses
Only two of the studies described intraoperative esti-
mated blood losses (EBLs) [13,14]. Both of these studies
reported that the EBLs did not significantly differ be-
tween the two approaches. In the studies of Baik et al.,
the hemoglobin change (g/dl) indices before and after
the surgical inventions were reported. These numbers
revealed no significant difference between the two
techniques [15]. The pooled data from these studies
suggested that the EBL of the RCS group was significantly
lower than that of the LCS group (WMD −20.10, 95%
CI −33.44 to −6.75; P = 0.003). Furthermore, there was
no evidence of observed heterogeneity (P = 0.59, I2 = 0%)
(Figure 5).
Conversion rate
Overall, conversions to open operations were required
for two patients in the RCS group (1.82%) and for 11
patients in the LCS group (9.48%). Analyses of the
pooled data revealed that the conversion rate was
significantly lower in the RCS group than in the LCS
group (WMD 0.25, 95% CI 0.07 to 0.91; P = 0.04), and
there was no obvious heterogeneity among the four
studies (P = 0.27, I2 = 24%) (Figure 6).Figure 5 Meta-analysis of the EBLs shown as a forest plot between rob
surgery (LCS). The mean differences with 95% CIs are shown.Time to recovery of bowel function
The time to first flatus was reported by Park et al. [13],
and the number of days to peristalsis was reported by
Baik et al. [15]; both of these variables are indicative of
the time to the recovery of bowel function. Analyses of
the pool data revealed that the RCS group exhibited
shorter times to the recovery of bowel function than
did the LCS group (WMD 0.54, 95% CI −0.93 to −0.14;
P =0.008, I2 = 0) (Figure 7).Length of hospital stay
Four of the studies reported the duration of hospital
stays. Baik et al. [15] revealed that the mean length
of the hospital stay (LOS) for all patients who under-
went laparoscopic procedures was longer than that of
those who underwent robotic procedures (P <0.001).
However, the other three studies reported no differ-
ences in hospital stays between the two groups. Ana-
lysis of all of the studies revealed no significant
difference between the two techniques in terms of LOS
(WMD −0.53, 95% CI −2.14 to 2.08; P = 0.52). However,
the heterogeneity was slightly high (P = 0.19, I2 = 51%)
(Figure 8).Complication rate
The complication rates were similar across studies,
and there was no significant heterogeneity (I2 = 0). A
meta-analysis of all of the studies in this index revealed
that the complication rates of the two group were not
obviously different (odds ratio (OR) 1.39, 95% CI 0.71
to 2.74, P = 0.33) (Figure 9).otic-assisted colorectal surgery (RCS) and laparoscopic colorectal
Figure 6 Meta-analysis of the conversion rates shown as a forest plot between robotic-assisted colorectal surgery (RCS) and laparoscopic
colorectal surgery (LCS). The odds ratios with 95% CIs are shown.
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Baik et al. [15] and Park et al. [13] reported proximal
margin indices, and there was no difference in this
regard (WMD −0.54, 95% CI −1.20 to 2.29; P = 0.54,
I2 = 0) (Figure 10). All of the studies reported distal
margins, and there was no difference between the
two groups in this regard (WMD 0.37, 95% CI − 0.79
to 1.54; P = 0.53) (Figure 11). The studies exhibited
significant heterogeneity (I2 = 71%); one study by
Patriti et al. [14] found a high SD for the LCS group
(7.2 cm), and, if this study was excluded, the hetero-
geneity was relatively low (I2 = 48%). The harvested
lymph nodes were similar across all of the studies
(I2 = 0), and analysis of the pooled data revealed that
the two groups did not differ significantly in this regard
(WMD 0.09, 95% CI −1.91 to 1.72; P = 0.92, I2 = 0)
(Figure 12).Costs
As a newly developing surgical technique, it should
prove to be safe and cost-effective until it is widely
accepted worldwide. Thus, it is essential to evaluate
the cost-effectiveness between RCS and LCS. In our
meta- analysis, only one study addressed to this issue.
Park et al. [13] reported that the overall hospital costs
were significantly higher in the RCS group (US $12235
versus $10319.7), as showed in Table 2. Based on the
limited data, it would be rash to make a conclusion
that RCS is not cost-effective.Figure 7 Meta-analysis of the times to the recovery of bowel function
surgery (RCS) and laparoscopic colorectal surgery (LCS). The mean diffPublication bias
Complications were assessed by a funnel plot of the
standard errors of the fixed-effect sizes between the
RCS and LCS. This analysis revealed no evidence of
publication bias or heterogeneity among the studies
(P = 0.55, Figure 13).
Sensitivity analysis
A sensitivity analysis was performed by excluding the
low-quality studies (that is, those with high risk of bias).
As shown in Figure 2, we considered the studies of
Patriti et al. [14] to have high risks of bias. All variables
were included for the sensitivity analysis. If one index
was not enough available in a sufficient number of studies
(that is, at least two), this index was excluded from further
sensitivity analysis. The sensitivity analysis revealed that
the operation times of the RCS group were longer than
that of the LCS group (WMD 35.97, 95% CI 3.83 to 68.10,
P = 0.03). There was no significant difference in the con-
version rates of the two techniques (OR 0.51, 95% CI 0.10
to 2.49; P = 0.41). Analyses of the times to recovery of
bowel function, complication rates, proximal margins,
distal margins, and the harvested lymph nodes yielded
similar results. However, the LOS of the RCS group
were significantly shorter than those of the LCS group
(WMD −1.35, 95% CI −2.34 to −0.37, P = 0.007).
Discussion
Laparoscopic surgery has been applied in many surgi-
cal fields and has not only been shown to be effectiveshown as a forest plot between robotic-assisted colorectal
erences with 95% CIs are shown.
Figure 8 Meta-analysis of length of hospital stays shown as a forest plot between robotic-assisted colorectal surgery (RCS) and laparoscopic
colorectal surgery (LCS). The mean differences with 95% CIs are shown.
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itional open surgery [17-19]. However, limitations to
the performance of laparoscopic surgery remain, in-
cluding the high conversion rate to open surgery [20].
The advent of robot-assisted surgery has overcome
some of the limitations of laparoscopic surgery and has
been successfully applied to urology, general surgery,
gynecology and other surgical fields [21,22]. Several
meta-analyses have suggested that robotic laparoscopic
surgery is feasible, produces similar perioperative outcomes
and is oncologically safe [23,24]. Robotic surgery may
result in shorter hospital stays, reduced blood losses and
lower conversion rates, but it also may require increased
operation time costs [24].
A previous meta-analysis [25] produced a similar
conclusion regarding the comparison of robotic lap-
aroscopic surgery to laparoscopic surgery in colorectal
disease. However, the studies that were included in this
previous meta-analysis were of relatively low quality,
and the number of patients was relatively small. Add-
itionally, the benefits of robotic surgery for colorectal
disease remain controversial. Thus, we conducted this
meta-analysis based on four RCTs to draw a clearer
conclusion.
The present study is the first meta-analysis to com-
pare robot-assisted and laparoscopic surgery for colo-
rectal cancer based only on RCTs. The results of this
meta-analysis revealed that RCS may provide additional
benefits over LCS and that it is safe and effectiveFigure 9 Meta-analysis of the complication rates shown as a forest plot
colorectal surgery (LCS). The odds ratios with 95% CIs are shown.[3,4,26]. Regarding operation times, RCS exhibited a
tendency to take longer than LCS, but this difference
was not significant (P = 0.06). This result is similar to
that of a previous study [27]. In contrast to this view,
other studies have reported that RCS requires more
time than does LCS [28,29]. As the surgeons’ robotic ex-
perience increases and the techniques are improved, the
operation times will be reduced [26]. However, in this
regard, obvious heterogeneity existed among the stud-
ies; the reasons for this heterogeneity were as follows.
First, the surgeries were performed by different sur-
geons who were not at the same point on the learning
curve and had different amounts of experience. Add-
itionally, the RCS group of one study contained a large
number of patients who had previously undergone ab-
dominal surgery [14], and it is well-known that previous
surgery inevitably increases the difficulty of performing
surgery.
EBL ranges between 90 ml and 320 ml for LCS [30]
and between 20 ml and 486 ml for RCS according to a
recently published review [31]. Our studies showed
that the average EBL was 81.83 ml for RCS and
92.88 ml for LCS. Both studies reported no significant
difference between the two groups in this regard. How-
ever, the pooled data revealed that the EBL was signifi-
cantly lower for the RCS group than for the LCS
group. This finding is consistent with those of previous
studies [31]. However, the surgery that was performed
by skilled surgical teams exhibited similarly low levelsbetween robotic-assisted colorectal surgery (RCS) and laparoscopic
Figure 10 Meta-analysis of the proximal margins shown as a forest plot between robotic-assisted colorectal surgery (RCS) and laparoscopic
colorectal surgery (LCS). The mean differences with the 95% CIs are shown.
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is possible to suggest that RCS may significantly reduce
the probability of transfusion and might prevent the
recurrence of cancer. A review reported that patients
who receive more perioperative transfused blood are at
greater risk for cancer recurrence and that this risk is
independent of tumor stage at surgery [32]. It is well-
known that the prognosis for colorectal cancer after
surgery is highly dependent on the cancer stage at
surgery. However, the EBL during colorectal cancer
surgery influences long-term survival according to a
previous study [33]. Massive blood loss during colo-
rectal cancer surgery is probably related to advanced
disease or the recurrence of cancer [34], preoperative
therapy (neoadjuvant therapy with either chemoradia-
tion or chemotherapy alone), unclear anatomy [35]
and the lack of experience of the surgical team rather
than the type of surgical approach. Because only two
studies reported EBL in this analysis, further studies
are necessary to prove whether RCS results in lower
blood loss.
We found that the conversion rate was signifi-
cantly lower in the RCS group and there was no
significant heterogeneity across the four studies. Thus,
the reduction in conversion rate may be one of the key
benefits of RCS. Conversion rate is a valuable index of
surgical quality. Lower conversion rates are associated
with fewer postoperative complications [20]. The re-
duction in conversion rate may be attributable to the
fact that robotic surgery can facilitate certain steps
in colorectal procedures. These procedures includeFigure 11 Meta-analysis of the distal margins shown as a forest plot be
colorectal surgery (LCS). The mean differences with the 95% CIs are shownsplenic flexure takedown, dissection of the inferior
mesenteric vessels, dissection in the narrow pelvis [36],
et cetera.
As observed in the studies, robotic surgery has
other advantages. The time to the recovery of bowel
function was shorter in the RCS than in the LCS
group. This reduction may be another potential bene-
fit of RCS because faster returns to normal diets are
associated with faster recoveries. We discovered that
the LOS was not significantly different between the
two groups; indeed, LOS was similar between the two
techniques [26]. The complication rates of the patients
who underwent RCS and LCS were similar. This finding
also demonstrates that RCS is as safe and feasible as
LCS [37]. Regarding the pathological details, there were
no differences between the two techniques in terms of
proximal margins, distal margins or harvested lymph
nodes.
Although we conducted this meta-analysis based on
four RCTs, this meta-analysis still has the following
limitations. First, the included studies were not double-
blind studies or even single-blind studies; the studies
may have been biased; therefore, the interpretation of
their results may also have been biased. Second,
although we focused on colorectal surgery, different
types of diseases (for example, rectal cancer, sigmoid
colon cancer, right colon cancer) that involved differ-
ent types of surgery were included, which may have
caused heterogeneity. Third, the surgery in the in-
cluded cases were not performed by the same surgeon,
and the experience and technique of the surgeons maytween robotic-assisted colorectal surgery (RCS) and laparoscopic
.
Figure 12 Meta-analysis of the harvested lymph nodes shown as a forest plot between robotic-assisted colorectal surgery (RCS) and
laparoscopic colorectal surgery (LCS). The mean differences with the 95% CIs are shown.
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ation time, EBL and conversion rate. However, in this
meta-analysis, no significant heterogeneities among
the four studies were found for conversion rate or EBL;
only operation time exhibited significant heterogen-
eity. Fourth, long-term follow-up evaluations assessing
oncologic outcomes were not available from the selected
studies, and only Patriti et al. [14] reported medium-term
outcomes. Fifth, the available included RCT studies
were limited, and the numbers of operations were small;
however, other RCT studies comparing RCS and LCS,
such as the ACOSOG Z6051 and ROLARR studies, are
ongoing [38]. Finally, only one study compared costs
between RCS and LCS [13]. This study revealed that the
overall hospital costs were significantly higher for RCS
than for LCS. Robotics is a new trend in colorectal sur-
gery, and more attention has been paid to the high cost
that is associated with this new technique. A variety of
studies have reported that the cost of robotic colorectal
surgery is higher than that of laparoscopic surgery
[3,39,40]. The high capital and running costs of roboticFigure 13 Funnel plot used to assess a fixed-effects model of the res
robotic-assisted colorectal surgery (RCS) and laparoscopic colorectalsystems have precluded their widespread use in many
countries [41]. Furthermore, one study reported that
RCS does not provide sufficient advantages over LCS
but significantly increases the total cost [38]. Future
studies should assess the cost-effectiveness of RCS
based on long-term oncologic outcomes and functional
results.
Conclusions
This meta-analysis suggests that RCS is safe and effect-
ive and has some advantages over LCS. These benefits
include a reduced conversion rate, reduced blood loss
and reduced time to recovery of bowel function. Re-
garding the other variables, such as operation time,
complication rate and LOS, there were no significant
differences between the two groups. However, RCS was
associated with a significant increase in total costs rela-
tive to LCS. Further well-designed, prospective con-
trolled randomized trials should be conducted to assess the
financial benefits and the long-term oncologic outcomes
of RCS.ults of all of the selected studies regarding the complications of
surgery (LCS). SE, standard error.
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